Temporal expression of matrix metalloproteinase (MMP)-1, -2, -3, -7, -8, -9, -12, and -13, and tissue inhibitors of metalloproteinases (TIMPs)-1 and -2 in human cervicovaginal fluid (CVF) in term pregnancy and labor was investigated. Term parous women provided CVF samples that were grouped into labor, 1 to 3, 6 to 8, and 12 to 16 days before labor onset. Both MMPs and TIMPs (n = 60) were quantified using multiplex solution array and enzyme-linked immunosorbent assays, respectively. Further analysis of TIMP-1 (n = 180) was undertaken. All MMPs and TIMPs except MMP-12 and -13 were detected in the CVF. Matrix metalloproteinase 7, TIMP-1, and TIMP-2 were significantly increased in labor. Tissue inhibitors of metalloproteinase 1 was significantly increased up to 7 days before spontaneous labor onset. The data suggest a role of MMP-7 in the remodeling and rupture of fetal membranes and may reflect the homeostatic regulation of extracellular matrix remodeling of MMP-7 by TIMP-1 and TIMP-2.
BrewKNagaseH. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71.
4.
SennströmMBBraunerAByströmBMalmströmAEkmanG. Matrix metalloproteinase-8 correlates with the cervical ripening process in humans. Acta Obstet Gynecol Scand. 2003;82(10):904–911.
5.
StygarDWangHVladicYS. Increased level of matrix metalloproteinases 2 and 9 in the ripening process of the human cervix. Biol Reprod. 2002;67(3):889–894.
6.
WatariMWatariHDiSantoME. Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells. Am J Pathol. 1999;154(6):1755–1762.
7.
YoshidaMSagawaNItohH. Nitric oxide increases matrix metalloproteinase-1 production in human uterine cervical fibroblast cells. Mol Hum Reprod. 2001;7(10):979–985.
8.
LedinghamMADenisonFCRileySCNormanJE. Matrix metalloproteinases-2 and -9 and their inhibitors are produced by the human uterine cervix but their secretion is not regulated by nitric oxide donors. Hum Reprod. 1999;14(8):2089–2096.
9.
XuPAlfaidyNChallisJR. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in human placenta and fetal membranes in relation to preterm and term labor. J Clin Endocrinol Metab. 2002;87(3):1353–1361.
10.
NishiharaSSomeyaAYonemotoH. Evaluation of the expression and enzyme activity of matrix metalloproteinase-7 in fetal membranes during premature rupture of membranes at term in humans. Reprod Sci. 2008;15(2):156–165.
11.
FortunatoSJMenonR. Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes. J Assist Reprod Genet. 2002;19(10):483–486.
12.
MooreRMMansourJMRedlineRWMercerBMMooreJJ. The physiology of fetal membrane rupture: insight gained from the determination of physical properties. Placenta. 2006;27(11-12):1037–1051.
13.
RohCROhWJYoonBKLeeJH. Up-regulation of matrix metalloproteinase-9 in human myometrium during labour: a cytokine-mediated process in uterine smooth muscle cells. Mol Hum Reprod. 2000;6(1):96–102.
14.
MaymonERomeroRPacoraP. Human neutrophil collagenase (matrix metalloproteinase 8) in parturition, premature rupture of the membranes, and intrauterine infection. Am J Obstet Gynecol. 2000;183(1):94–99.
15.
FortunatoSJMenonRLombardiSJ. Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -3 and -4) in human fetal membranes. Am J Reprod Immunol. 1998;40(6):395–400.
16.
BecherNHeinMDanielsenCCUldbjergN. Matrix metalloproteinases and their inhibitor in the cervical mucus plug at term of pregnancy. Am J Obstet Gynecol. 2004;191(4):1232–1239.
17.
BecherNHeinMDanielsenCCUldbjergN. Matrix metalloproteinases in the cervical mucus plug in relation to gestational age, plug compartment, and preterm labor. Reprod Biol Endocrinol. 2010;8:113.
18.
BecherNHeinMUldbjergNDanielsenCC. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP. Reprod Biol Endocrinol. 2008;6:45.
19.
ChoiSJJungKLOhSYKimJHRohCR. Cervicovaginal matrix metalloproteinase-9 and cervical ripening in human term parturition. Eur J Obstet Gynecol Reprod Biol. 2009;142(1):43–47.
20.
RahkonenLRutanenEMNuutilaM. Matrix metalloproteinase-8 in cervical fluid in early and mid pregnancy: relation to spontaneous preterm delivery. Prenat Diagn. 2010;30(11):1079–1085.
21.
Di QuinzioMKOlivaKHoldsworthSJ. Proteomic analysis and characterisation of human cervico-vaginal fluid proteins. Aust N Z J Obstet Gynaecol. 2007;47(1):9–15.
22.
HengYJDi QuinzioMKPermezelMRiceGEGeorgiouHM. Interleukin-1 receptor antagonist in human cervicovaginal fluid in term pregnancy and labor. Am J Obstet Gynecol. 2008;199(6):656.e1–e7.
23.
NugentRPKrohnMAHillierSL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301.
24.
KolkenbrockHOrgelDHecker-KiaANoackWUlbrichN. The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem. 1991;198(3):775–781.
25.
CrabbeTWillenbrockFEatonD. Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases. Biochemistry.1992;31(36):8500–8507.
26.
MiyazakiKFunahashiKNumataY. Purification and characterization of a two-chain form of tissue inhibitor of metalloproteinases (TIMP) type 2 and a low molecular weight TIMP-like protein. J Biol Chem. 1993;268(19):14387–14393.
27.
MaymonERomeroRPacoraP. Matrilysin (matrix metalloproteinase 7) in parturition, premature rupture of membranes, and intrauterine infection. Am J Obstet Gynecol. 2000;182(6):1545–1553.
28.
WoessnerJF. Matrix metalloproteinase inhibition. From The jurassic to the third millennium. Ann N Y Acad Sci. 1999;878:388–403.
29.
MurphyGCockettMIWardRVDochertyAJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan: a quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991;277(pt 1):277–279.
30.
HengYJDi QuinzioMKPermezelM. Temporal proteomic analysis of human cervicovaginal fluid with impending term labor. J Proteome Res. 2010;9(3):1344–1350.
31.
GoldmanSWeissAEyaliVShalevE. Differential activity of the gelatinases (matrix metalloproteinases 2 and 9) in the fetal membranes and decidua, associated with labour. Mol Hum Reprod. 2003;9(6):367–373.
32.
McLarenJTaylorDJBellSC. Increased concentration of pro-matrix metalloproteinase 9 in term fetal membranes overlying the cervix before labor: implications for membrane remodeling and rupture. Am J Obstet Gynecol. 2000;182(2):409–416.
33.
AgrezMGuXGilesW. Matrix metalloproteinase 9 activity in urine of patients at risk for premature delivery. Am J Obstet Gynecol. 1999;181(2):387–388.
34.
RomeroRChaiworapongsaTEspinozaJ. Fetal plasma MMP-9 concentrations are elevated in preterm premature rupture of the membranes. Am J Obstet Gynecol. 2002;187(5):1125–1130.
35.
MaymonERomeroRPacoraP. A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. J Perinat Med. 2001;29(4):308–316.
36.
OtaAYonemotoHSomeyaA. Changes in matrix metalloproteinase 2 activities in amnionchorions during premature rupture of membranes. J Soc Gynecol Investig. 2006;13(8):592–597.
37.
RileySCLeaskRDenisonFC. Secretion of tissue inhibitors of matrix metalloproteinases by human fetal membranes, decidua and placenta at parturition. J Endocrinol. 1999;162(3):351–359.
38.
PentlandAPShapiroSDWelgusHG. Agonist-induced expression of tissue inhibitor of metalloproteinases and metalloproteinases by human macrophages is regulated by endogenous prostaglandin E2 synthesis. J Invest Dermatol. 1995;104(1):52–57.
39.
LeppertPC. Cervical softening, effacement and dilatation: a complex biochemical cascade. J Matern Fetal Med. 1992;1:213–223.
40.
WinklerMOberpichlerATschescheH. Collagenolysis in the lower uterine segment during parturition at term: correlations with stage of cervical dilatation and duration of labor. Am J Obstet Gynecol. 1999;181(1):153–158.
41.
AthaydeNRomeroRGomezR. Matrix metalloproteinases-9 in preterm and term human parturition. J Matern Fetal Med. 1999;8(5):213–219.
42.
LeitichHEgarterCKaiderA. Cervicovaginal fetal fibronectin as a marker for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 1999;180(5):1169–1176.
43.
HonestHBachamannLMGuptaJKKleijnenJKhanKS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ. 2002;325(7359):301.
44.
Sanchez-RamosLDelkeIZamoraJKaunitzAM. Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis. Obstet Gynecol. 2009;114(3):631–640.
45.
ImaiMTaniASaitoM. Significance of fetal fibronectin and cytokine measurement in the cervicovaginal secretions of women at term in predicting term labor and post-term pregnancy. Eur J Obstet Gynaecol Reprod Biol. 2001;97(1):53–58.
46.
TimmonsBCMahendrooM. Processes regulating cervical ripening differ from cervical dilation and postpartum repair: insights from gene expression studies. Reprod Sci. 2007;14(8 suppl):53–62.
